Panadol is owned by Haleon plc, a British multinational consumer healthcare company. Haleon was formed in July 2022 as a spin-off from GlaxoSmithKline (GSK) and inherited a portfolio of well-known brands including Panadol, Sensodyne, and Voltaren. The company operates globally and is publicly traded, with major ownership by institutional investors such as Vanguard Group and BlackRock, along with a minority stake held by GSK after the spin-off.
